Open access peer-reviewed chapter

The Promising Role of Anti-Fibrotic Agent Halofuginone in Liver Fibrosis/Cirrhosis

Written By

Berna Karakoyun

Submitted: November 30th, 2016 Reviewed: March 20th, 2017 Published: July 5th, 2017

DOI: 10.5772/intechopen.68641

Chapter metrics overview

1,653 Chapter Downloads

View Full Metrics


Liver fibrosis is a complex inflammatory and fibrogenic process that results from chronic liver injury and represents an early step in the progression of cirrhosis. Several cell types [hepatic stellate cells (HSCs), hepatocytes, liver sinusoidal endothelial cells (LSECs), and Kupffer cells (KCs)], cytokines [platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β, tumor necrosis factor (TNF)-α, interferons (IFNs), interleukins (ILs)], oxidative stress, and microRNAs (miRNAs) are involved in the initiation and progression of liver fibrosis/cirrhosis. Generally, liver fibrosis begins with the stimulation of inflammatory immune cells to secrete cytokines, growth factors, and other activator molecules. These chemical mediators direct HSCs to activate and synthesize large amounts of extracellular matrix (ECM) components. Therefore, HSC activation is a pivotal event in the development of fibrosis and a major contributor to collagen (specifically type I) accumulation. The inhibitory effect of halofuginone on collagen type α1(I) synthesis and ECM deposition has been shown in several experimental models of fibrotic diseases. Halofuginone inhibits TGF-β–induced phosphorylation of Smad3, which is a key phenomenon in the fibrogenesis. It also regulates cell growth and differentiation, apoptosis, cell migration, and immune cell function in liver fibrosis/cirrhosis. This review discusses the etiology and mechanisms of liver fibrosis/cirrhosis and the promising role of anti-fibrotic agent halofuginone.


  • liver fibrosis
  • liver cirrhosis
  • hepatic stellate cells
  • pathogenesis
  • anti-fibrotic
  • halofuginone

1. Introduction

Liver cirrhosis is the end-stage condition of several chronic liver diseases, and fibrosis is the critical pre-stage of cirrhosis. On a worldwide perspective, liver cirrhosis can be induced by a number of well-defined etiological causes/factors or conditions such as chronic infection by hepatitis B, C viruses, chronic alcoholism and/or chronic exposure to toxins or drugs, infections, chronic exposure to altered metabolic conditions, inherited metabolic diseases such as hematochromatosis and Wilson’s disease, auto-immune diseases such as primary biliary cirrhosis, and auto-immune hepatitis [13]. These etiologies may work separately or in combination with each other to produce cumulative effects. While the causes of liver cirrhosis are multifactorial, there are some pathological characteristics that are common to all cases of cirrhosis, including degeneration and necrosis of hepatocytes, replacement of healthy liver parenchyma by fibrotic scar tissues and regenerative nodules, and loss of liver function [47].

Fibrosis is characterized by high levels of extracellular matrix (ECM, non-functional connective tissue) components extremely rich in collagen type I. The matrix metalloproteinases (MMPs, matrix degradation enzymes), and the tissue inhibitor of metalloproteinases (TIMPs) play a crucial role in the fine regulation of ECM turnover, which is altered in most pathological states associated with liver fibrosis [8]. The key cellular mediator of fibrosis comprises the activated hepatic stellate cells (HSCs), which serve as the primary ECM-producing cells. HSCs, which play a key role in the development of liver fibrosis [9, 10], are activated by several inflammatory cytokines and growth factors in a paracrine and autocrine manner [11, 12].

Liver fibrosis and cirrhosis are dynamic and highly integrated molecular, tissue and cellular processes that can progress and regress over time [13] and that require cellular cross-talk between various liver cell types [14]. At early stages of fibrosis, initiating signals [such as DNA, reactive oxygen species (ROS)], responding cells [Kupffer cells (KCs), platelets, liver sinusoidal endothelial cells (LSECs)], and soluble mediators [such as platelet-derived growth factor (PDGF), transforming growth factor (TGF)-β] induce accompanying wound-healing responses to liver injury. With time, cells, cytokine responses, and ECM components become more specialized but continue to have strong interactions with each other [15].

Halofuginone is a non-toxic plant alkaloid [7-bromo-6-chloro-3-(3-hydroxy-2-piperidine)-2-oxopropyl-4(3H)-quinazoline] isolated from the roots of Dichroa febrifuga, and is used worldwide as an anti-parasitic drug [16]. Independent of this effect, halofuginone was found to be a potent inhibitor of collagen type α1 (I) gene expression [17], which was demonstrated in a broad range of cell types both in vitroand in vivo[1620]. Due to its inhibitory effects on collagen synthesis (collagen type α1) and ECM deposition, halofuginone treatment was used in several experimental disease models characterized by excessive collagen accumulation, such as pulmonary, pancreatic and renal fibrosis [2123], scleroderma and chronic graft-versus-host disease [24], post-operative peritendinous and abdominal adhesions [25, 26], urethral and esophageal strictures [27, 28], wound repair [29], burn injury [30], renal injury [31, 32], injury-induced arterial intimal hyperplasia [33], colitis [34], and liver fibrosis and cirrhosis [3539]. Although the exact anti-fibrotic mechanism of halofuginone is not well understood, it was found that halofuginone affects collagen synthesis probably by inhibiting TGF-β-mediated Smad3 (intracellular protein) activation [40]. Halofuginone also regulates cell growth and differentiation, apoptosis, cell migration, and immune cell function [41]. It prevents concanavalin A-induced liver fibrosis by affecting T helper 17 (Th17) cell differentiation, which suggests a direct connection between the myofibroblasts/fibrosis pathway and the Th17 pro-inflammatory pathway [38]. In addition, halofuginone treatment effectively inhibits the delayed-type hypersensitivity response, indicating suppression of T cell–mediated inflammation in vivo[42]. Moreover, it is a potent inhibitor of nuclear factor (NF)-κB, pro-inflammatory cytokines and p38 mitogen-activated protein kinase (p38 MAPK) phosphorylation in activated T cells in vitro[42]. Also, it inhibits HSC proliferation and migration and up-regulates their expressions of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NF-κB [43].

Although there are no highly effective anti-fibrogenic agents currently available, the potential candidates that can specifically inhibit ECM components in general and specifically inhibit collagen type I in particular, are considered to be promising for the prevention and treatment of liver fibrosis/cirrhosis. The present review aims to clarify the etiology and mechanisms of liver fibrosis/cirrhosis and focus on the anti-fibrotic potential of a novel and promising agent, halofuginone.


2. Role of different cell types in liver fibrosis/cirrhosis

The liver is composed of parenchymal cells (hepatocytes) and non-parenchymal cells (HSCs, LSECs, and KCs). Both parenchymal and non-parenchymal cells are involved in the initiation and progression of liver fibrosis/cirrhosis (Table 1).

Cell typesRole in liver fibrosis/cirrhosisReferences
Hepatic stellate cells (HSCs)Main function is storage of vitamin A and other retinoids[7, 44]
Undergo a phenotypic switch from a quiescent type into an activated type (myofibroblast-like cells) by several inflammatory cytokines[46]
Activated HSCs are major contributors to collagen accumulation[47, 48]
HepatocytesHepatocyte-derived apoptotic bodies stimulate secretion of fibrogenic cytokines from KCs and promote HSC activation[5053]
Hypoxic hepatocytes become a primary source of TGF-β in cirrhotic stage[55]
Liver sinusoidal endothelial cells (LSECs)Defenestration and capillarization of LSECs lead to impaired substrate exchange and HSC activation[57, 61, 62]
Secrete IL-33 to activate HSCs[63]
Kupffer cells (KCs)Activated KCs secrete inflammatory cytokines, promote HSC activation, and stimulate cell proliferation[6569]
KC-derived TGF-β1 stimulates proliferation and collagen formation of HSCs[66]
Activated KCs kill HSCs by a caspase 9-dependent mechanism via TRAIL[72, 73]

Table 1.

Role of different cell types in liver fibrosis/cirrhosis.

Abbreviations: TGF-β, transforming growth factor-β; IL, interleukin; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

2.1. Hepatic stellate cells (HSCs)

HSCs are one of the non-parenchymal cells of the liver located in the perisinusoidal space (space of Disse) between hepatocytes and sinusoidal endothelial cells. HSCs are also known as fat-storing cells, perisinusoidal cells, lipocytes, or vitamin A-rich cells, and their main function is storage of vitamin A and other retinoids [7, 44]. HSCs show two different phenotypes: quiescent type in the healthy liver and activated type in the diseased one. Quiescent HSCs mostly function as vitamin A reserves [45]. However, in response to liver injury, inflammatory cytokines such as tumor necrosis factor (TNF)-α, TGF-β, interleukin (IL)-1, and PDGF promote HSCs to undergo a phenotypic switch from a quiescent, vitamin A storing cell into proliferative, α-smooth muscle actin (α-SMA)-positive, myofibroblast-like cells which contribute to fibrosis by producing the abnormal ECM components [46]. Therefore, HSC activation is a pivotal phenomenon in initiation and progression of liver fibrosis and a major contributor to collagen accumulation [47, 48].

2.2. Hepatocytes

Hepatocytes are the primary parenchymal component of the liver and play an important role in fibrosis/cirrhosis. They are the main targets of several hepatotoxic agents including hepatitis viruses, alcohol metabolites, and bile acids [11]. Liver injury either promotes apoptosis or triggers compensatory regeneration of hepatocytes [49]. Hepatocyte-derived apoptotic bodies stimulate secretion of fibrogenic cytokines from KCs and promote HSC activation via interaction of toll-like receptor (TLR)-9 with DNA, which is released from apoptotic hepatocytes [5053]. On the other hand, activated HSCs also act as phagocytes and phagocytize hepatocyte apoptotic bodies, which promote myofibroblasts survival and fibrogenesis [54]. Therefore, apoptosis of hepatocytes is a crucial event in liver injury and contributes to tissue inflammation, fibrogenesis, and development of cirrhosis. Also, in the cirrhotic stage, hypoxic hepatocytes become a primary source of TGF-β, which may augment liver fibrosis [55].

2.3. Liver sinusoidal endothelial cells (LSECs)

LSECs constitute the sinusoidal wall, also known as endothelium, or endothelial lining. The main characteristic of LSECs is having the fenestrae on the surface of the endothelium [56, 57]. The endothelial fenestrae control exchange of fluids, solutes, and particles between sinusoidal blood and hepatocytes [58]. In the healthy liver, the fenestrated endothelial cells prevent HSC activation through vascular endothelial growth factor-stimulated nitric oxide production [59]. However, LSECs have high endocytotic capacity [56, 60]. Upon liver injury, defenestration and capillarization of LSECs lead to impaired substrate exchange which is the major cause of hepatic dysfunction [57, 58] and HSC activation [61, 62]. It has been also revealed that LSECs can secrete the cytokine IL-33 to activate HSCs and promote liver fibrosis [63].

2.4. Kupffer cells (KCs)

KCs, also called stellate macrophages, are interspersed throughout the liver, situated within the sinusoids. KCs are responsible for the removal of circulating microorganisms, immune complexes, and debris from the blood stream. They are usually activated by many injurious factors such as viral infection and alcohol [64]. Activation of KCs is a key phenomenon in initiation and preservation of liver fibrosis. Activated KCs express chemokine receptors, secret inflammatory cytokines (such as TNF-α, IL-1, IL-6) and serve as antigen-presenting cells, which lead to progression of fibrosis [6568]. KCs are also involved in the activation of HSCs and formation of liver fibrosis. For example, KC-conditioned medium promotes activation of cultured rat HSCs with enhanced ECM production and stimulates cell proliferation via induction of PDGF receptors on the membrane of HSCs [69]. KC-derived TGF-β1 stimulates proliferation and collagen formation of HSCs in a rat model of alcoholic liver fibrogenesis [66]. Moreover, macrophage ablation has been shown to attenuate liver fibrosis. For example, gadolinium chloride-mediated depletion of KCs has been shown to result in attenuation of carbon tetrachloride (CCl4)-induced fibrosis in rats with prevention of the increased TGF-β expression [70]. Conversely, KCs produce interstitial collagenase MMP-13 when treated with gadolinium chloride, which reduces ECM deposition during experimental liver fibrosis [71]. In addition, activated KCs can effectively kill HSCs by a caspase 9-dependent mechanism via possible involvement of TNF-related apoptosis-inducing ligand (TRAIL) [72, 73].


3. Role of cytokines in liver fibrosis/cirrhosis

Cytokines, which mediate several immune and inflammatory reactions, are small signaling proteins that facilitate intercellular communication between various cells. They function through cell-surface receptors, and down-stream signaling induces an alteration of cell functions. Liver fibrosis/cirrhosis is a result of interaction of a complex network of cytokines, which modify activities of circulating immune cells, HSCs, KCs, LSECs, and hepatocytes. The role of cytokines in liver fibrosis/cirrhosis is summarized in Table 2.

MediatorsMechanism of actionReferences
Platelet-derived growth factor (PDGF)Activates HSCs[74]
Up-regulates expression of MMP-2, MMP-9, and TIMP-1 and inhibits collagenase activity[78]
Transforming growth factor (TGF)-βStimulates HSC activation[81, 82]
Induces expression of matrix-producing genes, inhibits ECM degradation, and promotes TIMPs[84, 85]
Inhibits DNA synthesis and induces apoptosis of hepatocytes[8688]
Tumor necrosis factor (TNF)-αInduces hepatocyte death by apoptosis[90]
Activates HSCs and stimulates ECM synthesis[91, 92]
Induces/reduces apoptosis of activated HSCs[73, 93]
Reduces glutathione and inhibits pro-collagen α1 mRNA expression[94]
Interferons (IFNs)
IFN-αTriggers apoptosis of HSCs[96]
Elicits an anti-apoptotic effect on activated HSCs[100]
IFN-βDecreases α-SMA and collagen expression and inhibits HSC activation through inhibition of TGF-β and PDGF[97]
IFN-γReduces ECM deposition by inhibiting HSC activation[98]
Exerts a pro-apoptotic effect on activated HSCs[100]
Interleukins (ILs)
IL-1Activates HSCs and stimulates them to produce MMP-9, MMP-13 and TIMP-1[102]
Increases MCP-1 in hepatocytes and augments TLR-4-dependent up-regulation of inflammatory signaling in macrophages[105]
IL-17Regulates production of TGF-β1 by KCs, induces activation of HSCs and induces production of collagen and α-SMA in HSCs via STAT3 pathway[108]
IL-6Attenuates hepatocyte apoptosis and induces regeneration of hepatocytes through NF-κB pathway[112]
IL-10Inhibits expression of TGF-β1, MMP-2 and TIMP-1[115]
Inhibits HSC activity[117]
Reduces TGF-β1, TNF-α, collagen α1, and TIMP mRNA up-regulation[120]
IL-22Inhibits hepatocyte apoptosis via STAT3[121, 122]
Induces HSC senescence[123]

Table 2.

Role of cytokines in liver fibrosis/cirrhosis.

Abbreviations: HSC, hepatic stellate cell; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; ECM, extracellular matrix; SMA, smooth muscle actin; MCP, monocyte chemoattractant protein; TLR, toll-like receptor; KC, Kupffer cell; STAT, signal transducer and activator of transcription; NF-κB, nuclear factor-κB.

3.1. Platelet-derived growth factor (PDGF)

PDGF is one of the most potent mitogen for HSCs isolated from mouse, rat, or human liver [74]. PDGF and its receptors are significantly overexpressed in fibrotic tissues, and its activity increases with the degree of liver fibrosis [75, 76]. Hepatocyte damage resulting from factors, such as viruses, chemicals, or hepatotoxins, can induce KCs to synthesize and release PDGF [77]. When PDGF binds to its specific receptor on the membrane of HSCs, it activates corresponding signal molecules and transcription factors, leading to the activation of its down-stream target genes and activation of HSCs [74]. PDGF has been shown to up-regulate the expression of MMP-2, MMP-9, and TIMP-1, and inhibit collagenase activity, thereby decreasing ECM degradation [78].

3.2. Transforming growth factor (TGF)-β

Among fibrotic mediators, TGF-β is one of the most important pro-fibrotic cytokine. The direct targets in TGF-β pathway, Smads (especially Smad3) are critical mediators in fibrogenesis [7980]. The intracellular effectors of TGF-β signaling, the Smad proteins, are activated by receptors and translocate into the nucleus, where they regulate transcription [79]. The main effect of TGF-β is to stimulate HSC activation, and the TGF-β autocrine cycle in activated HSCs is an important positive feedback to the progression of liver fibrosis [81, 82]. Though the main source of TGF-β in fibrotic liver is activated HSCs, LSECs, KCs, and hepatocytes also contribute to synthesis of this growth factor [83]. The level of TGF-β1 expression is increased during liver fibrosis and reaches a maximum at cirrhosis [55]. TGF-β1 induces expression of the matrix-producing genes, inhibits ECM degradation, and promotes TIMPs, leading to excessive collagen accumulation and promoting the development of liver fibrosis [84, 85]. Furthermore, TGF-β1 has been shown to inhibit DNA synthesis and induces apoptosis of hepatocytes. In particular, TGF-β1-induced apoptosis is thought to be responsible for tissue loss and decrease in liver size seen in cirrhosis [8688].

3.3. Tumor necrosis factor (TNF)-α

TNF-α is a pro-inflammatory cytokine produced by different cell types. However, it is mainly produced by activated KCs in the liver. TNF-α is an important mediator in several processes such as cell proliferation, inflammation, and apoptosis [89]. TNF-α can induce cell death by apoptosis, and KCs can be stimulated by apoptotic hepatocytes to produce more TNF-α [90]. Furthermore, TNF-α plays an essential role in the HSC activation and ECM synthesis in liver fibrosis [91, 92]. TNF-α may act as surviving factor for activated rat HSCs by up-regulating the anti-apoptotic factors (NF-κB, bcl-xL, and p21WAF1) and by down-regulating the pro-apoptotic factor (p53) [93]. On the other hand, TNF-α can induce apoptosis in HSCs [73]. It has been also demonstrated that TNF-α shows anti-fibrogenic effect in rat HSCs by reducing glutathione and inhibiting pro-collagen α1 mRNA expression [94].

3.4. Interferons (IFNs)

IFNs are potent pleiotropic cytokines that broadly alter cellular functions in response to viral and other infections. Leukocytes synthesize IFN-α and IFN-β in response to viruses, and T cells secrete IFN-γ upon stimulation with various antigens and mitogens. Although the primary action of IFN-α is to eradicate viruses, patients with hepatitis C treated with IFN-α exhibit a regression of liver fibrosis even if viral eradication is not achieved [95], indicating that IFN-α itself has anti-fibrotic activity via triggering the apoptosis of HSCs [96]. IFN-β treatment decreases α-SMA and collagen expression and inhibits HSC activation through inhibition of TGF-β and PDGF pathways [97]. Similarly, IFN-γ reduces ECM deposition in vivoby inhibiting HSC activation [98] via TGFβ1/Smad3 signaling pathways [99]. Interestingly, IFN-α and IFN-γ may exert opposite effects on apoptosis in HSCs. IFN-α was shown to elicit an anti-apoptotic effect on activated HSCs, whereas IFN-γ was found to exert pro-apoptotic effect on HSCs by down-regulating heat-shock protein 70 [100].

3.5. Interleukins (ILs)

ILs are immunomodulatory cytokines that are critically involved in the regulation of immune responses. They are produced by a variety of cell types such as CD4+ T lymphocytes, monocytes, macrophages, and endothelial cells. KCs and LSECs can rapidly produce ILs in response to liver injury. ILs can have pro- and anti-inflammatory functions in chronic liver diseases, dependent on the inflammatory stimulus and, the producing and the responding cell type.

The main function of pro-inflammatory ILs is to stimulate immune responses that result in the elimination of invading pathogens or damaged cells. On the other hand, anti-inflammatory ILs are produced to protect the host’s body from exaggerated immune responses and to limit organ damage. As soon as the pathogenic stimuli are removed, ILs production is no longer needed, and inflammation diminishes. If the stimulus continues, inflammation can become chronic and induce a variety of inflammatory diseases [101].

IL-1 is a pro-inflammatory and pro-fibrotic cytokine that directly activates HSCs and stimulates them to produce MMP-9, MMP-13, and TIMP-1, resulting in liver fibrogenesis [102]. IL-1 receptor-deficient mice exhibits ameliorated liver damage and reduced fibrogenesis [102]. Similarly, IL-1 receptor antagonist protects rats from developing fibrosis in dimethylnitrosamine-induced liver fibrosis [103]. Lack of IL-1α or IL-1β also makes the mice less susceptible to develop liver fibrosis in experimental model of steatohepatitis [104]. It has been also shown that IL-1β at physiological doses increases the inflammatory and prosteatotic chemokine monocyte chemoattractant protein (MCP)-1 in hepatocytes, and augments TLR-4-dependent up-regulation of inflammatory signaling in macrophages [105]. Thus, IL-1 is an important participant, along with other cytokines, and controls the progression from liver injury to fibrogenesis.

Another pro-inflammatory and pro-fibrotic cytokine IL-17 has been reported to be involved in many immune processes, most notably in inducing and mediating pro-inflammatory responses. Its expression increases with increasing degree of liver fibrosis [106, 107], suggesting that IL-17 may not only induce inflammation but also contribute to disease progression and chronicity [106]. IL-17 regulates production of TGF-β1 by KCs, which in turn, induces activation of HSCs into myofibroblasts, and further facilitates differentiation of IL-17 expressing cells [108]. Also, IL-17 directly induces production of collagen and α-SMA in HSCs via the signal transducer and activator of transcription (STAT)3 signaling pathway [108]. Furthermore, abrogation of IL-17 signaling by deletion of IL-17RA protects mice from fibrogenesis [108]. Similarly, blockade of endogenous IL-17 with neutralizing IL-17-specific antibody reduces liver fibrosis, whereas treatment with recombinant IL-17 increases fibrosis development [109].

IL-6 is a pleiotropic cytokine, which may affect differentiation of fibroblast to myofibroblast, and it plays an important role in fibrotic diseases [110, 111]. On the other hand, IL-6 has beneficial effects for the liver. For example, IL-6 reduces CCl4-induced acute and chronic liver injury and fibrosis [112]. Also, it attenuates hepatocyte apoptosis and induces regeneration of hepatocytes through NF-κB signaling pathway [112]. In an experimental model of concavaline A-induced hepatitis, IL-6 pretreatment protects mice from liver injury. This protection requires gp130 signaling in hepatocytes and is mediated via the gp130/STAT3 signaling cascade [113]. Furthermore, systemic injection of IL-6 followed by intrahepatic transplantation of mesenchymal stem cells is also able to reduce hepatocyte apoptosis and liver fibrogenesis after CCl4 treatment [114].

IL-10 is one of the major anti-inflammatory cytokines, with tissue protective functions during fibrogenesis. It down-regulates the pro-inflammatory response and has a modulatory effect on liver fibrogenesis [115, 116]. IL-10 has been shown to exert anti-fibrotic effects through inhibiting HSC activity [117]. IL-10-deficient mice show higher liver fibrosis with larger inflammatory infiltrates in CCl4-induced liver fibrosis compared to wild-type mice [118, 119]. IL-10 gene therapy reverses CCl4-induced murine liver fibrosis by inhibiting the expression of TGF-β1, MMP-2, and TIMP-1 [115]. Additionally, IL-10 gene therapy reverses liver fibrosis and prevents cell apoptosis in a thioacetamide-treated murine liver, and reduces TGF-β1, TNF-α, collagen α1, and TIMP mRNA up-regulation, suggesting a therapeutic potential for treatment with IL-10 [120].

IL-22 is known to play important roles in the modulation of tissue immune responses to inflammation. It reduces inflammation-induced damage of hepatocytes both in vitroand in vivoby promoting their survival and inhibiting apoptosis [121]. This protective function is dependent on STAT3 signaling, as STAT3-deficient mice were not protected when treated with IL-22 [122]. Similarly, in CCl4-induced liver fibrogenesis, IL-22 is protective through induction of senescence in HSCs via STAT3 signaling pathway [123]. Moreover, IL-22 is also involved in the restoration of functional liver mass after organ damage. Liver progenitor cells have been shown to express IL-22R, and IL-22 derived from inflammatory cells induces proliferation of liver progenitor cells [124].


4. Role of oxidative stress in liver fibrogenesis

Oxidative stress is caused by an imbalance between production of ROS and their elimination by anti-oxidant defenses [125]. As liver is an essential organ for detoxification and nutrients metabolism, it is more vulnerable to oxidative stress [125]. Oxidative stress-related molecules and pathways modulate tissue and cellular events involved in the liver fibrogenesis [126]. The generation of ROS plays a crucial role in producing liver damage and initiating liver fibrogenesis [126]. Oxidative stress disrupts lipids, proteins and DNA, induces necrosis and apoptosis of hepatocytes, resulting in the initiation of fibrosis [127]. ROS stimulate the production of pro-fibrogenic mediators from KCs and circulating inflammatory cells. Remarkably, ROS directly activate HSCs. The elevated oxidative stress contributes to fibrogenesis via stimulating collagen production from activated HSCs and release of other pro-fibrogenic cytokines and growth factors [126, 128].


5. Role of microRNAs (miRNAs) in liver pathophysiology

miRNAs are a family of small non-coding RNAs (20–25 nucleotides in length) that control gene expression by binding to mRNAs to repress translation or induce mRNA cleavage [129]. Many researchers have reported that the unusual expression of miRNAs in liver tissue was related to the pathogenesis of liver disease of any etiology [130, 131]. Recently, miRNAs have been found to play fundamental roles in liver fibrosis, including those in HSC activation and ECM production [132]. For example, miRNA-21 exhibits an important role in the pathogenesis and progression of liver fibrosis. A natural product 3,3′-Diindolylmethane (DIM) inhibits TGF-β signaling pathway by down-regulating the miRNA-21 expression in thioacetamide-induced experimental liver fibrosis. Furthermore, DIM can suppress HSC activation via down-regulatingmiRNA-21 levels in HSCs by inhibiting activity of the transcription factor AP-1 [133]. Inhibition of miRNA-21 also reduces liver fibrosis through concomitant reduction of CD24+ liver progenitor cells [134]. In mouse and human studies, the expression levels of miRNA-199a, antisense miRNA-199a*, miRNA-200a, and miRNA-200b are found to be positively and significantly correlated with progression of liver fibrosis. Overexpression of these miRNAs dramatically increases the expression of fibrosis-related genes in HSCs [135]. Also, miRNA-221 and miRNA-222 are up-regulated in human liver in a fibrosis progression-dependent manner [136]. Similarly, in isolated primary human liver cells, miRNA-571 is up-regulated in hepatocytes and HSCs in response to the pro-fibrogenic cytokine TGF-β [137]. miRNA-214 appears to participate in the development of liver fibrosis by modulating the epidermal growth factor (EGF) receptor and TGF-β signaling pathways. Also, inhibition of miRNA-214 by locked nucleic acid-antimiRNA-214 ameliorates liver fibrosis in PDGF c transgenic mice [138]. In addition, miRNA-214-5p may play crucial roles in HSC activation and progression of liver fibrosis. The overexpression of miRNA-214-5p in human stellate cells increases the expression of fibrosis-related genes such as MMP-2, MMP-9, α-SMA, and TGF-β1 [139].

miRNAs may also play anti-fibrogenic roles. It has been demonstrated that both miRNA-150 and miRNA-194 inhibit HSC activation and ECM production in rats with liver fibrosis by decreasing the expression of c-myb (target for miRNA-150) and rac 1 (target for miRNA-194) [140]. Interestingly, miRNAs such as miRNA-19b, miRNA-29, miRNA-133a, and miRNA-146a are significantly down-regulated in HSCs isolated from experimental animals with liver fibrosis, and restoration of these miRNAs alleviates fibrogenesis [47, 141, 142]. Moreover, miRNA-133a overexpression inhibits both human and murine primary HSCs proliferation and prevents the progression of liver fibrosis [142].

Multiple studies have proposed that miRNAs may serve as biomarkers for HSC activation and liver fibrosis progression, and can be possible candidates for future therapies targeting liver fibrosis/cirrhosis.


6. Pathogenesis of liver fibrosis/cirrhosis

Liver fibrosis and its end-stage consequence, cirrhosis, represent the final common pathway of almost all chronic liver diseases. Fibrosis and cirrhosis of the liver remain major medical problems with significant morbidity and mortality worldwide. Liver fibrosis is in fact a wound-healing response to liver injury and is characterized by accumulation of fibrotic scar tissue. Although the scar tissue formation is beneficial at first because it encapsulates the injury, the chronic activation of this healing process eventually progresses to advanced fibrosis/cirrhosis. This leads to altered vascular architecture and microcirculation, ischemia, and widespread hepatocyte cell death [143]. Also, in cirrhosis, collagen strands become so prevalent and divide the liver parenchyma into distinct structurally abnormal regenerative nodules, resulting in organ dysfunction [143].

In fact, liver damage leading to cirrhosis is the result of a complex mechanism involving, from direct toxic effects to a sustained inflammatory process, driving to the death of hepatocytes via apoptosis and liver fibrosis, mediated by secretion of several cytokines [144]. The inflammatory reaction is the coordinated process by which the liver responds to local insults, trying to restore the hepatic architecture and function after acute liver injury [128]. However, if the liver is faced to a sustained local damage, the chronic inflammatory response gives rise to a progressive replacement of healthy liver tissue by non-functional fibrotic scar tissue. The imbalance between tissue regeneration and fibrosis determines the outcome toward health recovery or liver cirrhosis [144].

6.1. Imbalance between extracellular matrix synthesis and degradation

Liver fibrosis can be defined as a dynamic and highly integrated molecular, tissue and cellular process regarded as the result of an imbalance between ECM synthesis and degradation. In the healthy liver, ECM is composed of several components such as collagens (mainly the interstitial types I, III, V, VI, and the basement membrane types IV, XV, XVIII, and XIX), glycoproteins (such as laminin isoforms and fibronectin), proteoglycans and elastin [145147]. Normally, ECM components comprise less than 3% of the relative area of a liver tissue section and approximately 0.5% of the wet weight. During the development of liver fibrosis, there is a 5- to 10-fold increase in the content of collagenous and non-collagenous components, particularly of fibrillar collagen type I and III [146], and an increase of elastin, laminins, and proteoglycans [148]. The total amount of ECM is not only dependent on the rate of synthesis but also largely on the balance between the matrix MMPs, and the TIMPs, especially TIMP-1 [15].

The MMPs are a family of zinc-dependent endopeptidases that can degrade both collagenous and non-collagenous components of ECM in the extracellular space [149]. MMP activity is regulated by TIMPs, which bind to MMPs, blocking their proteolytic activity. The MMPs and TIMPs play a crucial role in the fine regulation of the ECM turnover and the resulting increase in the TIMPs/MMPs ratio in liver promotes fibrosis by protecting accumulated matrix from degradation by MMPs (Figure 1) [8].

Figure 1.

Imbalances in ECM synthesis and degradation result in liver fibrosis. Regulation of degradation is determined by the balance between the activity of MMPs and TIMPs. The MMPs degrade both collagenous and non-collagenous components of ECM in the extracellular space. MMP activity is regulated by TIMPs, which bind to MMPs, blocking their proteolytic activity. Increase in the TIMPs/MMPs ratio in liver promotes fibrosis by protecting accumulated matrix from degradation by MMPs. ECM, extracellular matrix; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitor of metalloproteinases.

6.2. Mechanisms and mediators of liver fibrogenesis

Liver fibrosis, which is characterized by the excessive deposition of ECM (non-functional connective tissue) components [150], involves both parenchymal and non-parenchymal cells, as well as infiltrating immune cells [151, 152]. Furthermore, several critical signaling pathways have important roles in liver fibrosis. The complex interactions between these signaling pathways and different cells contribute to the progression of liver fibrosis [153].

HSCs are central effectors of fibrogenesis although other cells and processes can make significant contributions. In the healthy liver, HSCs are in a quiescent state with low proliferation rates, store dietary vitamin A, control the ECM synthesis, regulate the local vascular contractility, and serve as the pericytes for the sinusoidal endothelial cells. Damage to hepatocytes activates HSCs transformation into myofibroblast-like cells that play a fundamental role in the development of fibrotic liver response [14]. Myofibroblast-like cells with high proliferative capacity, without vitamin A, exhibit increased expression of α-SMA fibers [3]. These cells contribute to fibrosis by producing large amounts of ECM components and collagens (specifically type I) to encapsulate the injury [152]. Although HSCs are classically considered to be a major source of myofibroblasts [154, 155], other cell types like portal myofibroblasts and cells recruited from the bone marrow also contribute to the expansion of the myofibroblast population observed during the liver injury [154]. Activated HSCs also secrete an increased amount of MMPs and their inhibitors, TIMPs, which are necessary for the ECM remodeling [154, 156]. HSC activation leads to the up-regulation of TIMPs and TGF-β1 with the inhibition of MMP activity. The TIMP activation thus stimulates collagen type I synthesis and ECM deposition in the extracellular space [157]. Besides injured hepatocytes, hepatic macrophages (KCs), endothelial cells, and lymphocytes also drive HSC activation [158].

HSC activation is still the primary pathway leading to the liver fibrosis and it consists of two main stages: initiation and perpetuation (Figure 2) [126]. The initiation stage is related with the early changes in gene expression and phenotype that render the cells responsive to several cytokines and stimuli. Initiation of HSC activation is stimulated by several soluble factors such as oxidant stress signals (ROS), apoptotic bodies, and paracrine stimuli from neighboring cell types including hepatocytes, KCs, sinusoidal endothelium, and platelets [872]. Hepatocytes are believed to represent a major source of ROS as well as of other oxidative stress-related reactive mediators or intermediates [1]. Hepatocyte apoptosis leads to the release of cellular contents such as DNA and ROS that activate KCs to release pro-inflammatory (such as TNF-α, IL-1β, IL-6, MCP-1) and pro-fibrogenic (especially TGF-β) factors [158]. Hepatocyte apoptosis following injury also promotes initiation of HSC activation through a process mediated by Fas, and this process may involve the TRAIL [159]. After stimulation by cytokines or engulfment of apoptotic bodies, KCs stimulate matrix synthesis and cell proliferation through the actions of cytokines including TGF-β1 and ROS/lipid peroxides [64]. Endothelial cells are also likely to participate by conversion of TGF-β from the latent to the active, pro-fibrogenic form [126]. Platelets are another important source of paracrine stimuli, including PDGF, TGF-β1, and EGF [126]. On the other hand, perpetuation stage results from the effects of these stimuli on maintaining the activated phenotype and generating liver fibrosis. This stage involves autocrine as well as paracrine cycles. It includes HSC activation and related cellular changes such as proliferation, chemotaxis, fibrogenesis, contractility, and matrix degradation [126]. Activated HSCs proliferate in response to various kinds of cytokines, chemokines, and growth factors such as TGF-β, EGF, and PDGF [2, 8]. TGF-β, which has been identified as the most pro-fibrotic cytokine, promotes expression of collagen type I by activated HSCs and inhibits ECM degradation through the expression of TIMPs [160]. In parallel, PDGF has emerged as the most potent proliferative cytokine for HSCs [8]. Also, activated HSCs show chemotactic response, migrate toward damaged area and start to accumulate [3]. They express the cytoskeleton protein (α-SMA), equipping the cells with a contractile apparatus and collagens (especially type I) [12, 161, 162]. Thus, HSCs are able to constrict individual sinusoids as well as the entire fibrotic liver [3]. The net effect of these changes is to increase ECM deposition. In addition, cytokine release by HSCs can expand the inflammatory and fibrogenic tissue responses, and matrix proteases may hasten the replacement of normal matrix with fibrotic scar [126]. Briefly, activated HSCs are major effectors of liver fibrogenesis by integrating all incoming paracrine or autocrine signals released from both parenchymal and non-parenchymal cells (pro-inflammatory cytokines, growth factors, chemokines, ROS, and others).

Figure 2.

Initiation, perpetuation, and regression of liver fibrogenesis involving HSCs. The pathways of HSC activation consist of initiation and perpetuation. Initiation is stimulated by soluble factors such as apoptotic bodies, oxidant stress signals (ROS), and paracrine stimuli from neighboring cell types. Perpetuation includes HSC activation (phenotypic switch from a quiescent type into an activated type) and related cellular changes such as proliferation, chemotaxis, fibrogenesis, contractility, and abnormal matrix degradation. Repetitive damage to liver causes perpetuation of activated HSCs in the liver. Activated HSCs produce excessive collagen, down-regulate release of MMPs and enhance expression of the physiological inhibitors of the MMPs (TIMPs). Imbalances in collagen synthesis and degradation result in liver fibrosis/cirrhosis. During regression, activated HSCs undergo apoptosis or inactivation if the cause of liver injury is removed. ROS, reactive oxygen species; KC, Kupffer cell; HSC, hepatic stellate cell; TNF-α, tumor necrosis factor-α; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; TGF-β, transforming growth factor-β; TIMPs, tissue inhibitor of metalloproteinases; MMPs, matrix metalloproteinases; TRAIL, TNF-related apoptosis-inducing ligand.

Chronic inflammation and fibrosis are inseparably linked and the interactions between immune cells, local fibroblasts and especially subsets of macrophages determine the outcome of liver injury [8]. Macrophage phenotype and function are critical determinants of fibrotic scarring or resolution of injury. Macrophages, which are typically categorized into classically activated (M1) or alternatively activated (M2) phenotypes, play dual roles in the progression and resolution of liver fibrosis [163]. Typically, M1 macrophages play a pro-inflammatory role in liver injury and produce inflammatory cytokines, while M2 macrophages exert an anti-inflammatory role during tissue repair and fibrosis. The imbalance of M1 and M2 macrophages mediates the progression and resolution of liver fibrosis [164]. During the early stages of liver injury, bone marrow-derived monocytes are extensively recruited to the liver and then differentiate into inflammatory macrophages (mostly M1 macrophages) to produce pro-inflammatory and pro-fibrotic cytokines, thereby promoting inflammatory responses and HSC activation. Afterwards, recruited macrophages switch their phenotypes (mostly M2 macrophages) to secrete MMPs for the successful resolution in hepatic scar [153, 165, 166]. Therefore, a complicated interplay between M1 and M2 types of macrophages plays a critical role in fibrogenesis [128].

6.3. Liver fibrosis is potentially reversible

Liver fibrosis is thought to be a potentially reversible condition if the cause of liver injury is removed (such as virus suppression or alcohol absence) (Figure 2). Regression of liver fibrosis is associated either with elimination of activated HSCs via apoptosis or senescence or with reversion of activated HSCs to a more quiescent phenotype. It has been shown that HSCs are sensitive to Fas and TRAIL-mediated apoptosis, and natural killer cells can induce apoptosis of HSCs by a TRAIL-mediated mechanism [167]. Similarly, TRAIL expressed by KCs is also thought to mediate HSC apoptosis [168]. In addition, apoptosis of activated HSCs is for sure followed by a decrease in collagen production as well as a reduction in TIMP synthesis with an increase in the hepatic MMP expression [1]. Therefore, activated HSCs, the primary source of ECM, are the most attractable target for reversing liver fibrosis [169].


7. Halofuginone

Halofuginone, a non-toxic and low molecular weight plant alkaloid [7-bromo-6-chloro-3-(3-hydroxy-2-piperidine)-2-oxopropyl-4(3H)-quinazoline] (Figure 3) isolated from the roots of Dichroa febrifuga(Chinese medicinal plant), is used worldwide as an anti-parasitic drug in commercial poultry production [16]. At first, halofuginone was identified as a potent inhibitor of collagen type α1 gene expression and ECM deposition. At present, it is being evaluated in clinical trial for Duchenne muscular dystrophy, in which fibrosis is the main complication.

Figure 3.

Chemical structure of halofuginone.

7.1. Halofuginone and its effect on collagen synthesis

Halofuginone was found to be a potent inhibitor of collagen type α1 gene expression [17], which was demonstrated in a broad range of cell types including rat, mouse, chicken, and human, both in vitroand in vivo[1620]. The discovery of the inhibitory effect of halofuginone on collagen synthesis and ECM deposition has led to intensive studies that were aimed to control many diseases associated with excessive collagen accumulation, such as pulmonary, pancreatic and renal fibrosis [2123], scleroderma and chronic graft-versus-host disease [24], post-operative peritendinous and abdominal adhesions [25, 26], urethral and esophageal strictures [27, 28], wound repair [29], burn injury [30], renal injury [31, 32], injury-induced arterial intimal hyperplasia [33], colitis [34], and liver fibrosis and cirrhosis [3539]. Inhibition is independent of the route of administration (intraperitoneally, administered locally, or given orally).

Halofuginone was found to inhibit collagen type I synthesis but not that of type II [17] or III [170] in vitro. The inhibitor effect of halofuginone on collagen α1 synthesis appears not to be a direct effect but rather dependent on new protein synthesis, because concurrent treatment of fibroblasts with protein synthesis inhibitors blocks the suppressive effect of halofuginone on collagen α1 mRNA gene expression [18].

Because of the significant impact of fibrosis on human health, there is an unmet need for safe and effective therapies that directly target fibrosis. In animal models of fibrosis, regardless of the tissue, halofuginone had a minimal effect on collagen levels in the control (non-fibrotic) animals; however, it displayed a strong inhibitory effect in the fibrotic organs. This suggests that the regulation of the low-level expression of collagen type I genes differs from that of the overexpression induced by the fibrogenic stimulus, which is usually an aggressive and rapid process [171]. Halofuginone mainly affects the stimulated collagen synthesis, therefore, when it is administered systemically, it is actually targeted to the desired fibrotic location without affecting collagen synthesis in other regions.

7.2. Halofuginone and TGF-β pathway

TGF-β is a “master switch” in chronic liver disease, being involved in all stages of the disease progression, from initial liver injury, inflammation, fibrosis, to cirrhosis and hepatocellular carcinoma at the end [172]. TGF-β signals through transmembrane receptor serine/threonine kinases to activate novel signaling intermediates called Smad proteins, which then modulate transcription of target genes [173]. TGF-β, signaling via Smad3, is the most pro-fibrogenic cytokine present in the liver and the major promoter of ECM synthesis [173, 174]. It induces pro-fibrotic cellular and transcriptional responses such as induction of the synthesis of ECM components, especially collagen, as well as fibronectin and laminin, and it inhibits the matrix degradation enzymes [175]. In various experimental fibrotic models, no effect of halofuginone was observed on the expression of the TGF-β receptors gene or on TGF-β levels [176178]. This finding supports the hypothesis that the halofuginone target is down-stream in the TGF-β pathway. Halofuginone is an inhibitor of Smad3 phosphorylation down-stream of the TGF-β signaling pathway [177, 179, 180]. In chemically induced liver fibrosis, halofuginone affects TGF-β regulated genes through inhibition of Smad3 phosphorylation of activated HSCs [181]. It inhibits TGF-β-induced phosphorylation of Smad3 and also increases the expression of the inhibitory Smad7 in several cell types (such as fibroblasts, hepatic and pancreatic stellate cells, tumor cells and myoblasts) [178, 181183]. The inhibition of Smad3 phosphorylation is associated with the halofuginone-dependent activation of Akt MAPK/ERK and p38 MAPK phosphorylation [182]. Thus, drugs that selectively target individual signaling pathways down-stream of the TGF-β receptor are likely to be more successful.

7.3. Halofuginone affects pre-existing fibrosis

Halofuginone affects fibrosis as a preventive agent when it was administered before or together with the fibrotic stimulus [21, 26, 27, 35, 184]. It can elicit resolution of established fibrosis, a capability that sets it apart from all other preventive anti-fibrotic agents. For example, in rats with established thioacetamide-induced liver fibrosis, addition of halofuginone to the diet results in almost complete resolution of the fibrotic condition as measured by hydroxyproline levels in the liver [36]. This is probably due to up-regulation of the collagen degradation pathway by inhibition of the TIMP-1, and activation of MMPs [43]. In addition, halofuginone given orally before fibrosis induction prevents the activation of most of the stellate cells and the remaining cells expressed low levels of collagen α1 gene, resulting in low levels of collagen [36]. Furthermore, halofuginone administration in low concentrations prior to and following partial hepatectomy in cirrhotic rats does not inhibit normal liver regeneration, despite the reduced levels of collagen type I mRNA [37]. When given to rats with established fibrosis, halofuginone causes significant reductions in α-SMA, TIMP-2, collagen type I gene expression, and collagen accumulation [37]. These animals demonstrate improved capacity for regeneration, suggesting the possible beneficial use of halofuginone before and during fibrotic/cirrhotic liver regeneration.

7.4. Halofuginone as an anti-fibrotic agent

In recent years, much attention was focused on halofuginone against liver fibrosis (Table 3). Although the exact anti-fibrotic mechanism of halofuginone is not well understood, it is found to be associated with inhibition of TGF-β signaling [179], which is known to inhibit mesengial cell proliferation and ECM deposition [185]. In several animal models of fibrosis, in which excess collagen is the characteristic of the disease, halofuginone prevents transition of the fibroblasts to myofibroblasts by inhibition of Smad3 phosphorylation down-stream of the TGF-β signaling pathway [186, 187], thereby inhibits collagen synthesis [186]. Halofuginone also regulates cell growth and differentiation, apoptosis, cell migration, and immune cell function [41]. It prevents concanavalin A-induced liver fibrosis by affecting Th17 cell differentiation, which suggests a direct link between the myofibroblasts/fibrosis pathway and the Th17 pro-inflammatory pathway [38]. Th17 cells, a distinct subset of CD4+ T cells with IL-17 as their major cytokine, orchestrate the pathogenesis of inflammation [171]. It has been suggested that halofuginone-dependent inhibition of fibrosis includes selective inhibition of the Th17 cell development by activating the amino acid starvation response [188, 189]. Halofuginone activates the amino acid starvation response by directly inhibiting the prolyl-tRNA synthetase activity of glutamyl-prolyl-tRNA synthetase [190]. Furthermore, addition of exogenous proline reverses a broad range of halofuginone-induced cellular effects, indicating that glutamyl-prolyl-tRNA synthetase-inhibition underlies the therapeutic activities of halofuginone [190]. TGF-β is required for facilitation of differentiation of the inflammatory Th17 cell subset [191], which suggests the presence of a connection between the TGF-β signaling inhibition and the amino acid starvation response [187]. Treatment with halofuginone also effectively inhibits the delayed-type hypersensitivity response, indicating suppression of T cell–mediated inflammation in vivo[42]. Moreover, it was shown that halofuginone is a potent inhibitor of NF-κB, pro-inflammatory cytokines, and p38 MAPK phosphorylation in activated T cells in vitro[42]. Also, submicromolar concentrations of halofuginone inhibit HSC proliferation and migration and up-regulate their expression of fibrolytic MMP-3 and -13 via activation of p38 MAPK and NF-κB. The remarkable induction of MMP-3 and -13 makes halofuginone a promising agent for anti-fibrotic combination therapies [43]. Halofuginone also affects the cross-talk between the hepatocytes and the HSCs by up-regulating the synthesis and secretion of insulin-like growth factor binding protein-1 (IGFBP-1), which inhibits HSC migration [192]. It also affects the expression of early genes of liver regeneration, IGFBP-1 whose synthesis and secretion is regulated in part by TGF-β [192] and tyrosine phosphatase (PRL-1) whose synthesis is regulated by transcription factor early growth response-1 (Egr-1) probably via TGF-β [193].

DMN-induced liver fibrosis/cirrhosis in ratsPrevents liver cirrhosisPrevents increase in collagen type I gene expression[35]
TAA-induced liver fibrosis in ratsCauses almost complete resolution of fibrosisReduces collagen levels, collagen α1(I) gene expression, TIMP-2 content, and SMA-positive cells[36]
TAA-induced liver cirrhosis in ratsImproves liver regenerationReduces α-SMA, TIMP-2, collagen type I gene expression, and collagen accumulation[37]
ConA-induced liver fibrosis in ratsPrevents liver fibrosisDecreases Th17 cell differentiation and its related cytokines production[38]
ConA-induced liver fibrosis in ratsAttenuates liver fibrosisSuppresses synthesis of collagen 1, α-SMA and TIMP-2; down-regulates TGF-β1/Smad3 signaling pathway; decreases pro-inflammatory cytokines[39]
TAA-induced liver fibrosis in ratsUp-regulates MMP-3 and -13 and down-regulates TIMP-1 (in vivo); inhibits HSC proliferation and migration (in vitro)Activates p38 MAPK and NF-κB[43]
TAA-induced liver fibrosis in ratsInhibits HSC activation and collagen synthesis; prevents activation of TGF-β-dependent genesInhibits Smad3 phosphorylation[181]
TAA-induced liver fibrosis in ratsAffects cross-talk between hepatocytes and HSCsUp-regulates synthesis and secretion of IGFBP-1[192]
TAA-induced liver fibrosis in ratsPrevents liver fibrosis and improves cirrhotic liver regenerationIncreases expression of early genes of regeneration (PRL-1 and IGFBP-1)[193]
Human hepatoma cell injected miceSuppresses tumor growthIncreases IFN-γ and IL-2[196]
Diethylnitrosamine and N-nitrosomorpholine-induced HCC in ratsSuppresses lung metastasisInhibits MMP[197]

Table 3.

Effects of halofuginone in various experimental liver diseases.

Abbreviations: DMN, dimethylnitrosamine; TAA, thioacetamide; TIMP, tissue inhibitor of metalloproteinase; SMA, smooth muscle actin; ConA, Concanavalin A; Th17, T helper 17; TGF-β, transforming growth factor-β; MMP, matrix metalloproteinase; HSC, hepatic stellate cell; p38 MAPK, p38 mitogen-activated protein kinase; NF-κB, nuclear factor-κB; IGFBP-1, insulin-like growth factor binding protein-1; PRL-1, tyrosine phosphatase; IFN-γ, interferon-γ; IL-2, interleukin-2; HCC, hepatocellular carcinoma.

7.5. Anti-tumoral role of halofuginone

In many types of tumor, there is a strong relationship between tissue fibrosis and increased risk of tumor development. For example, the leading risk factor for hepatocellular carcinoma is liver cirrhosis, and its associated inflammation, regeneration, and fibrosis [194, 195]. Tumor cells develop and metastasize more effectively in fibrotic tissues; therefore, any reduction in tissue fibrosis reduces the risk of cancer [171]. Halofuginone reduces tumor growth and mortality in xenograph mice implanted with human hepatoma cells [196]. In diethylnitrosamine and N-nitrosomorpholine-induced, spontaneously metastasizing hepatocellular carcinoma, halofuginone suppresses lung metastasis in rats through MMP inhibition [197]. Moreover, halofuginone treatment results in effective inhibitory effects on the cascade of events leading to angiogenesis (formation of new blood vessels), such as abrogation of endothelial cell MMP-2 expression, basement membrane invasion, capillary tube formation, vascular sprouting, and deposition of sub-endothelial ECM in vitro[171]. Inhibition of angiogenesis is mostly accompanied by inhibition of the fibroblasts to myofibroblasts transition, reduction in tumor stroma ECM, and inhibition of tumor growth [171]. The high effectiveness of halofuginone in reducing fibrosis, which affects tumor growth and tissue regeneration in the liver, arises from its dual role in inhibiting the TGF-β signaling and Th17 cell development [187].


8. Conclusion

Fibrosis is a pathological process associated with excessive ECM deposition that leads to destruction of organ architecture and function. Fibrosis contributes enormously to deaths worldwide; thus, effective therapies are of a great need. Halofuginone has great potential as an anti-fibrotic therapeutic. Systemic administration of halofuginone in animal models and humans is well tolerated [24]. Additionally, in most animal models of fibrosis, halofuginone has a minimal effect on collagen levels in non-fibrotic animals, while exerting strong inhibitory effects in fibrotic organs. It mainly affects stimulated collagen synthesis without altering the usual low physiological level of collagen expression. Because halofuginone inhibits collagen type I synthesis on the transcriptional level and reduces ECM deposition, it is a promising candidate for treatment of diseases associated with excessive ECM, such as liver fibrosis/cirrhosis. Thus, halofuginone meets the criteria as a promising anti-fibrotic drug for further evaluation in the treatment of liver fibrosis/cirrhosis.


  1. 1. Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Archives of Biochemistry and Biophysics. 2014;548:20-37. DOI: 10.1016/
  2. 2. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World Journal of Gastroenterology. 2014;20(23):7312-7324. DOI: 10.3748/wjg.v20.i23.7312
  3. 3. Ahmad A, Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi Journal of Gastroenterology. 2012;18(3):155-167. DOI: 10.4103/1319-3767.96445
  4. 4. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. Journal of Clinical Pathology. 1978;31(5):395-414. DOI: 10.1136/jcp.31.5.395
  5. 5. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Archives of Pathology & Laboratory Medicine. 2000;124(11):1599-1607. DOI: 10.1043/0003-9985(2000)124<1599:ROHC>2.0.CO;2
  6. 6. Ferrell L. Liver pathology: Cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems. Modern Pathology. 2000;13(6):679-704. DOI: 10.1038/modpathol.3880119
  7. 7. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis. 2005;10(5):927-939. DOI: 10.1007/s10495-005-1055-4
  8. 8. Xu R, Zhang Z, Wang F. Liver fibrosis: Mechanisms of immune-mediated liver injury. Cellular and Molecular Immunology. 2012;9(4):296-301. DOI: 10.1038/cmi.2011.53
  9. 9. Zhang D, Zhao Y, Wei D, Li Y, Zhang Y, Wu J, et al. HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. Journal of Hepatology. 2012;57(6):1283-1291. DOI: 10.1016/j.jhep.2012.07.042
  10. 10. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. Journal of Gastroenterology and Hepatology. 2007;22(s1):S73–S78. DOI: 10.1111/j.1440-1746.2006.04658.x
  11. 11. Bataller R, Brenner DA. Liver fibrosis. The Journal of Clinical Investigation. 2005;115:209-218. DOI: 10.1172/JCI24282
  12. 12. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: Molecular mechanisms and drug targets. Annual Review of Pharmacology and Toxicology. 2005;45(1):605-628. DOI: 10.1146/annurev.pharmtox.45.120403.095906
  13. 13. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Seminars in Liver Disease. 2001;21(03):427-436. DOI: 10.1055/s-2001-17557
  14. 14. Kmiec Z. Cooperation of liver cells in health and disease. Advances in Anatomy, Embryology and Cell Biology. 2001;161:III–XIII. PMID: 11729749
  15. 15. Mehal WZ, Schuppan D. Antifibrotic therapies in the liver. Seminars in Liver Disease. 2015;35(02):184-198. DOI: 10.1055/s-0035-1550055
  16. 16. Granot I, Bartov I, Plavnik I, Wax E, Hurwitz S, Pines M. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Poultry Science. 1991;70(7):1559-1563. DOI: 10.3382/ps.0701559
  17. 17. Granot I, Halevy O, Hurwitz S, Pines M. Halofuginone: An inhibitor of collagen type I synthesis. Biochimica et Biophysica Acta (BBA)—General Subjects. 1993;1156(2):107-112. DOI: 10.1016/0304-4165(93)90123-p
  18. 18. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone. Biochemical Pharmacology. 1996;52(7):1057-1063. DOI: 10.1016/0006-2952(96)00427-3
  19. 19. Nagler A, Miao HQ, Aingorn H, Pines M, Genina O, Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17(1):194-202. DOI: 10.1161/01.atv.17.1.194
  20. 20. Pines M, Nagler A: Halofuginone: A novel antifibrotic therapy. General Pharmacology. 1998;30(4):445-450. DOI: 10.1016/s0306-3623(97)00307-8
  21. 21. Nagler A, Firman N, Feferman R, Cotev S, Pines M, Shoshan S. Reduction in pulmonary fibrosis in vivo by halofuginone. American Journal of Respiratory and Critical Care Medicine. 1996;154(4):1082-1086. DOI: 10.1164/ajrccm.154.4.8887611
  22. 22. Benchetrit S, Yarkoni S, Rathaus M, Pines M, Rashid G, Bernheim J, Bernheim J. Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats. Israel Medical Association Journal. 2007;9(1):30-34. PMID: 17274353
  23. 23. Karatas A, Paksoy M, Erzin Y, Carkman S, Gonenc M, Ayan F, et al. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis. Journal of Surgical Research. 2008;148(1):7-12. DOI: 10.1016/j.jss.2008.03.015
  24. 24. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biology of Blood and Marrow Transplantation. 2003;9(7):417-425. DOI: 10.1016/s1083-8791(03)00151-4
  25. 25. Nyska M, Nyska A, Rivlin E, Porat S, Pines M, Shoshan S, et al. Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery. Connective Tissue Research. 1996;34(2):97-103. DOI: 10.3109/03008209609021495
  26. 26. Nagler A, Rivkind AI, Raphael J, Levi-Schaffer F, Genina O, Lavelin I, et al. Halofuginone—an inhibitor of collagen type I synthesis—prevents postoperative formation of abdominal adhesions. Annals of Surgery. 1998;227(4):575-582. DOI: 10.1097/00000658-199804000-00021
  27. 27. Nagler A, Gofrit O, Ohana M, Pode D, Genina O, Pines M. The effect of halofuginone, an inhibitor of collagen type 1 synthesis, on urethral stricture formation: In vivo and in vitro study in a rat model. The Journal of Urology. 2000;164(5):1776-1780. DOI: 10.1016/s0022-5347(05)67105-4
  28. 28. Özçelik M, Pekmezci S, Sarıbeyoğlu K, Ünal E, Gümüştaş K, Doğusoy G. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of esophageal strictures related to caustic injury. The American Journal of Surgery. 2004;187(2):257-260. DOI: 10.1016/j.amjsurg.2003.11.008
  29. 29. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia. 1999;1(4):321-329. DOI: 10.1038/sj.neo.7900043
  30. 30. Cerit KK, Karakoyun B, Yüksel M, Ercan F, Tuğtepe H, Dagli TE, et al. Halofuginone alleviates burn-induced hepatic and renal damage in rats. Journal of Burn Care & Research. 2017;38(1):e384-e394. DOI: 10.1097/bcr.0000000000000400
  31. 31. Karakoyun B, Yuksel M, Turan P, Arbak S, Alican I. Halofuginone has a beneficial effect on gentamicin-induced acute nephrotoxicity in rats. Drug and Chemical Toxicology. 2009;32(4):312-318. DOI: 10.1080/01480540902976911
  32. 32. Karadeniz Cerit K, Karakoyun B, Yüksel M, Özkan N, Çetinel Ş, Tolga Dağli E, et al. The antifibrotic drug halofuginone reduces ischemia/reperfusion-induced oxidative renal damage in rats. Journal of Pediatric Urology. 2013;9(2):174-183. DOI: 10.1016/j.jpurol.2012.01.015
  33. 33. Liu K, Sekine S, Goto Y, Iijima K, Yamagishi I, Kondon K, et al. Halofuginone inhibits neointimal formation of cultured rat aorta in a concentration-dependent fashion in vitro. Heart and Vessels. 1998;13(1):18-23. DOI: 10.1007/bf02750639
  34. 34. Karakoyun B, Yüksel M, Ercan F, Salva E, Işık I, Yeğen BC. Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis. Digestive Diseases and Sciences. 2010;55(3):607-616. DOI: 10.1007/s10620-009-0798-0
  35. 35. Pines M, Knopov V, Genina O, Lavelin I, Nagler A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. Journal of Hepatology. 1997;27(2):391-398. DOI: 10.1016/s0168-8278(97)80186-9
  36. 36. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology. 2001;33(2):379-386. DOI: 10.1053/jhep.2001.21408
  37. 37. Spira G, Mawasi N, Paizi M, Anbinder N, Genina O, Alexiev R, et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. Journal of Hepatology. 2002;37(3):331-339. DOI: 10.1016/s0168-8278(02)00164-2
  38. 38. Liang J, Zhang B, Shen RW, Liu JB, Gao MH, Geng X, et al. The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis. Scandinavian Journal of Immunology. 2014;79(3):163-172. DOI: 10.1111/sji.12144
  39. 39. Liang J, Zhang B, Shen RW, Liu JB, Gao MH, Li Y, et al. Preventive effect of halofuginone on concanavalin A-induced liver fibrosis. PLoS ONE. 2013;8(12):e82232. DOI: 10.1371/journal.pone.0082232
  40. 40. Nelson EF, Huang CW, Ewel JM, Chang AA, Yuan C. Halofuginone down-regulates Smad3 expression and inhibits the TGF beta-induced expression of fibrotic markers in human corneal fibroblasts. Molecular Vision. 2012;18:479-487. PMID: 22393274
  41. 41. Flanders KC. Smad3 as a mediator of the fibrotic response. International Journal of Experimental Pathology. 2004;85(2):47-64. DOI: 10.1111/j.0959-9673.2004.00377.x
  42. 42. Leiba M, Cahalon L, Shimoni A, Lider O, Zanin-Zhorov A, Hecht I, et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. Journal of Leukocyte Biology. 2006;80(2):399-406. DOI: 10.1189/jlb.0705409
  43. 43. Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. Journal of Biological Chemistry. 2006;281(22):15090-15098. DOI: 10.1074/jbc.m600030200
  44. 44. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. New England Journal of Medicine. 1993;328(25):1828-1835. DOI: 10.1056/NEJM199306243282508
  45. 45. Lepreux S, Desmoulière A. Human liver myofibroblasts during development and diseases with a focus on portal (myo)fibroblasts. Frontiers in Physiology. 2015;6:173. DOI: 10.3389/fphys.2015.00173
  46. 46. Alison MR, Vig P, Russo F, Bigger BW, Amofah E, ThemisM, et al. Hepatic stem cells: From inside and outside the liver? Cell Proliferation. 2004;37(1):1-21. DOI: 10.1111/j.1365-2184.2004.00297.x
  47. 47. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology. 2012;56(1):300-310. DOI: 10.1002/hep.25613
  48. 48. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, et al. Inhibition of inhibitor of kappa B kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology. 2005;128(1):108-120. DOI: 10.1053/j.gastro.2004.10.003
  49. 49. Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, et al. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. AJP: Gastrointestinal and Liver Physiology. 2012;303(4):G498-G506. DOI: 10.1152/ajpgi.00525.2011
  50. 50. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Laboratory Investigation. 2003;83(5):655-663. DOI: 10.1097/01.lab.0000069036.63405.5c
  51. 51. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology. 2006;43(3):435-443. DOI: 10.1002/hep.21093
  52. 52. Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, Flavell RA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007;46(5):1509-1518. DOI: 10.1002/hep.21867
  53. 53. Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Seminars in Liver Disease. 2010;30(04):402-410. DOI: 10.1055/s-0030-1267540
  54. 54. Jiang JX, Mikami K, Venugopal S, Li Y, Török NJ. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways. Journal of Hepatology. 2009;51(1):139-148. DOI: 10.1016/j.jhep.2009.03.024
  55. 55. Jeong WI, Do SH, Yun HS, Song BJ, Kim SJ, Kwak WJ, et al. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver International. 2004;24(6):658-668. DOI: 10.1111/j.1478-3231.2004.0961.x
  56. 56. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: A review. Comparative Hepatology. 2002;1(1):1. DOI: 10.1186/1476-5926-1-1
  57. 57. Mori T, Okanoue T, Sawa Y, Hori N, Ohta M, Kagawa K. Defenestration of the sinusoidal endothelial cell in a rat model of cirrhosis. Hepatology. 1993;17(5):891-897. DOI: 10.1002/hep.1840170520
  58. 58. Yokomori H, Oda M, Yoshimura K, Hibi T. Recent advances in liver sinusoidal endothelial ultrastructure and fine structure immunocytochemistry. Micron. 2012;43(2-3):129-134. DOI: 10.1016/j.micron.2011.08.002
  59. 59. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology. 2008;48(3):920-930. DOI: 10.1002/hep.22351
  60. 60. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. Journal of Ultrastructure Research. 1970;31(1-2):125-150. DOI: 10.1016/S0022-5320(70)90150-4
  61. 61. DeLeve LD. Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology. 2015;61(5):1740-1746. DOI: 10.1002/hep.27376
  62. 62. Xie G, Wang X, Wang L, Atkinson RD, Kanel GC, Gaarde WA, et al. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology. 2012;142(4):918-927.e6. DOI: 10.1053/j.gastro.2011.12.017
  63. 63. Marvie P, Lisbonne M, L’helgoualc’h A, Rauch M, Turlin B, Preisser L, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. Journal of Cellular and Molecular Medicine. 2009;14(6b):1726-1739. DOI: 10.1111/j.1582-4934.2009.00801.x
  64. 64. Bilzer M, Roggel F, Gerbes AL. Role of kupffer cells in host defense and liver disease. Liver International. 2006;26(10):1175-1186. DOI: 10.1111/j.1478-3231.2006.01342.x
  65. 65. Xidakis C, Ljumovic D, Manousou P, Notas G, Valatas V, Kolios G, et al. Production of pro- and anti-fibrotic agents by rat Kupffer cells; the effect of octreotide. Digestive Diseases and Sciences. 2005;50(5):935-941. DOI: 10.1007/s10620-005-2668-8
  66. 66. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by kupffer cell-derived transforming growth factor beta: Implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology. 1990;11(4):599-605. DOI: 10.1002/hep.1840110412
  67. 67. Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Experimental and Molecular Pathology. 2001;71(3):226-240. DOI:10.1006/exmp.2001.2399
  68. 68. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World Journal of Gastroenterology. 2006;12(46):7413-7420. DOI: 10.3748/wjg.v12.i46.7413
  69. 69. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. Journal of Clinical Investigation. 1989;84(6):1780-1785. DOI: 10.1172/JCI114362
  70. 70. Rivera CA, Bradford BU, Hunt KJ, Adachi Y, Schrum LW, Koop DR, et al. Attenuation of CCl4-induced hepatic fibrosis by GdCl3 treatment or dietary glycine. AJP: Gastrointestinal and Liver Physiology. 2001;281(1):G200–G207. PMID: 11408273
  71. 71. Hironaka K, Sakaida I, Matsumura Y, Kaino S, Miyamoto K, Okita K. Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis. Biochemical and Biophysical Research Communications. 2000;267(1):290-295. DOI: 10.1006/bbrc.1999.1910
  72. 72. Fischer R, Cariers A, Reinehr R, Haussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology. 2002;123(3):845-861. DOI: 10.1053/gast.2002.35384
  73. 73. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology. 2003;37(1):87-95. DOI: 10.1053/jhep.2003.50002
  74. 74. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Frontiers in Bioscience. 2002;7(1-3):d1720-d1726. DOI: 10.2741/pinzani
  75. 75. Thieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, et al. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene. 2008;423(1):23-28. DOI: 10.1016/j.gene.2008.05.022
  76. 76. Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, et al. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. Journal of Clinical Investigation. 2010;120(7):2379-2394. DOI: 10.1172/JCI41203
  77. 77. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Laboratory Investigation. 2004;84(6):766-777. DOI: 10.1038/labinvest.3700094
  78. 78. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. Journal of Hepatology. 2006;45(3):419-428. DOI: 10.1016/j.jhep.2006.04.010
  79. 79. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature. 2003;425(6958):577-584. DOI:10.1038/nature02006
  80. 80. Wang C, Song X, Li Y, Han F, Gao S, Wang X, et al. Low-dose paclitaxel ameliorates pulmonary fibrosis by suppressing TGF-β1/Smad3 pathway via miR-140 upregulation. PLoS ONE. 2013;8(8):e70725. DOI: 10.1371/journal.pone.0070725
  81. 81. Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Letters. 2004;559(1-3):107-110. DOI: 10.1016/S0014-5793(04)00037-7
  82. 82. Cui X, Shimizu I, Lu G, Itonaga M, Inoue H, Shono M, et al. Inhibitory effect of a soluble transforming growth factor beta type II receptor on the activation of rat hepatic stellate cells in primary culture. Journal of Hepatology. 2003;39(5):731-737. DOI: 10.1016/s0168-8278(03)00216-2
  83. 83. De Bleser PJ, Niki T, Rogiers V, Geerts A. Transforming growth factor beta gene expression in normal and fibrotic rat liver. Journal of Hepatology. 1997;26(4):886-893. DOI: 10.1016/s0168-8278(97)80257-7
  84. 84. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver International. 2006;26(1):8-22. DOI: 10.1111/j.1478-3231.2005.01192.x
  85. 85. Cui Q, Wang Z, Jiang D, Qu L, Guo J, Li Z. HGF inhibits TGF-β1-induced myofibroblast differentiation and ECM deposition via MMP-2 in Achilles tendon in rat. European Journal of Applied Physiology. 2011;111(7):1457-1463. DOI: 10.1007/s00421-010-1764-4
  86. 86. Kirmaz C, Terzioglu E, Topalak O, Bayrak P, Yilmaz O, Ersoz G, Sebik F. Serum transforming growth factor beta1(TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C [corrected]. European Cytokine Network. 2004;15(2):112-116. [PMID: 15319169]
  87. 87. Oberhammer F, Pavelka M, Sharma S, Tiefenbacher R, Purchio A, Bursch W, et al. Induction of apoptosis in cultured hepatocytes and in recessing liver by transforming growth factor-beta1. Proceedings of the National Academy of Science of the United States of America. 1992;89(12):5408-5412. DOI: 10.1073/pnas.89.12.5408
  88. 88. Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor-beta1. Cancer Research. 1992;52(2):385-388. PMID: 1309441
  89. 89. McClain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver diseases IV. Dysregulated cytokine metabolism in alcoholic liver disease. AJP: Gastrointestinal and Liver Physiology. 2004;287(3):G497-G502. DOI: 10.1152/ajpgi.00171.2004
  90. 90. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003;38(5):1188-1198. DOI: 10.1053/jhep.2003.50472
  91. 91. Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A, et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. Journal of Clinical Investigation. 2009;119(11):3213-3225. DOI: 10.1172/JCI37581
  92. 92. Crespo J, Rivero M, Fábrega E, Cayón A, Amado JA, García-Unzeta MT, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Digestive Diseases and Sciences. 2002;47(7):1604-1610. PMID: 12141823
  93. 93. Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. European Journal of Cell Biology. 2001;80(8):554-561. DOI: 10.1078/0171-9335-00182
  94. 94. Varela-Rey M, Fontán-Gabás L, Blanco P, López-Zabalza MJ, Iraburu MJ. Glutathione depletion is involved in the inhibition of procollagen alpha1(I) mRNA levels caused by TNF-alpha on hepatic stellate cells. Cytokine. 2007;37(3):212-217. DOI: 10.1016/j.cyto.2007.03.013
  95. 95. Shiratori Y1, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Annals of Internal Medicine. 2000;132(7):517-524. DOI: 10.7326/0003-4819-132-7-200004040-00002
  96. 96. Ogawa T, Kawada N, Ikeda K. Effect of natural interferon α on proliferation and apoptosis of hepatic stellate cells. Hepatology International. 2009;3(3):497-503. DOI: 10.1007/s12072-009-9129-y
  97. 97. Rao HY, Wei L, Wang JH, Fei R, Jiang D, Zhang Q, et al. Inhibitory effect of human interferon-beta-1a on activated rat and human hepatic stellate cells. Journal of Gastroenterology and Hepatology. 2010;25(11):1777-1784. DOI: 10.1111/j.1440-1746.2010.06264.x
  98. 98. Baroni GS, D’Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology. 1996;23(5):1189-1199. DOI: 10.1002/hep.510230538
  99. 99. Du S, Li H, Cui Y, Yang L, Wu J, Huang H, et al. Houttuynia cordata inhibits lipopolysaccharideinduced rapid pulmonary fibrosis by up-regulating IFN-γ and inhibiting the TGF-β1/Smad pathway. International Immunopharmacology. 2012;13(3):331-340. DOI: 10.1016/j.intimp.2012.03.011
  100. 100. Saile B, Eisenbach C, Dudas J, El-Armouche H, Ramadori G. Interferon-gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates the antiapoptotic effect of interferon alpha by an HSP70-dependant pathway. European Journal of Cell Biology. 2004;83(9):469-476. DOI: 10.1078/0171-9335-00409
  101. 101. Hammerich L, Tacke F. Interleukins in chronic liver disease: Lessons learned from experimental mouse models. Clinical and Experimental Gastroenterology. 2014;7:297-306. DOI: 10.2147/ceg.s43737
  102. 102. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. AJP: Gastrointestinal and Liver Physiology. 2009;296(6):G1324-G1331. DOI: 10.1152/ajpgi.90564.2008
  103. 103. Mancini R, Benedetti A, Jezequel AM. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Archive. 1994;424(1):25-31. DOI: 10.1007/BF00197389
  104. 104. Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. Journal of Hepatology. 2011;55(5):1086-1094. DOI: 10.1016/j.jhep.2011.01.048
  105. 105. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. Journal of Clinical Investigation. 2012;122(10):3476-3489. DOI: 10.1172/JCI60777
  106. 106. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, et al. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagnostic Pathology. 2013;8:40. DOI: 10.1186/1746-1596-8-40
  107. 107. Hara M, Kono H, Furuya S, Hirayama K, Tsuchiya M, Fujii H. Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. Journal of Surgical Research. 2013;183(2):574-582. DOI: 10.1016/j.jss.2013.03.025
  108. 108. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143(3):765-776.e1-3. DOI: 10.1053/j.gastro.2012.05.049
  109. 109. Zheng L, Chu J, Shi Y, Zhou X, Tan L, Li Q, et al. Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell and Bioscience. 2013;3(1):46. DOI: 10.1186/2045-3701-3-46
  110. 110. Shahar I, Fireman E, Topilsky M, Grief J, Kivity S, Spirer Z, et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clinical Immunology and Immunopathology. 1996;79(3):244-251. DOI: 10.1006/clin.1996.0075
  111. 111. Wynn TA. Cellular and molecular mechanisms of fibrosis. Journal of Pathology. 2008;214(2):199-210. DOI: 10.1002/path.2277
  112. 112. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology. 2000;31(1):149-159. DOI: 10.1002/hep.510310123
  113. 113. Klein C, Wüstefeld T, Assmus U, Roskams T, Rose-John S, Müller M, et al. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. Journal of Clinical Investigation. 2005;115(4):860-869. DOI: 10.1172/JCI23640
  114. 114. Nasir GA, Mohsin S, Khan M, Shams S, Ali G, Khan SN, et al. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. Journal of Translational Medicine. 2013;11:78. DOI: 10.1186/1479-5876-11-78
  115. 115. Chou WY, Lu CN, Lee TH, Wu CL, Hung KS, Concejero AM, et al. Electroporative interleukin-10 gene transfer ameliorates carbon tetrachloride-induced murine liver fibrosis by MMP and TIMP modulation. Acta Pharmacologica Sinica. 2006;27(4):469-476. DOI: 10.1111/j.1745-7254.2006.00304.x
  116. 116. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders. Gastroenterology. 2000;1188(4):655-660. DOI: 10.1016/S0016-5085(00)70134-X
  117. 117. Zhang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, Zhang SJ, et al. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology. 2007;54(79):2092-2098. PMID: 18251166
  118. 118. Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology. 1998;28(6):1597-1606. DOI: 10.1002/hep.510280620
  119. 119. Louis H, Van Laethem JL, Wu W, Quertinmont E, Degraef C, Van den Berg K, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology. 1998;28(6):1607-1615. DOI: 10.1002/hep.510280621
  120. 120. Hung KS, Lee TH, Chou WY, Wu CL, Cho CL, Lu CN, et al. Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochemical and Biophysical Research Communications. 2005;336(1):324-331. DOI: 10.1016/j.bbrc.2005.08.085
  121. 121. Radaeva S, Sun R, Pan HN, Hong F, Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004;39(5):1332-1342. DOI: 10.1002/hep.20184
  122. 122. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. Hepatology. 2010;52(4):1291-1300. DOI: 10.1002/hep.23837
  123. 123. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012;56(3):1150-1159. DOI: 10.1002/hep.25744
  124. 124. Feng D, Kong X, Weng H, Park O, Wang H, Dooley S, et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology. 2012;143(1):188-198.e7. DOI: 10.1053/j.gastro.2012.03.044
  125. 125. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, et al. The role of oxidative stress and antioxidants in liver diseases. International Journal of Molecular Sciences. 2015;16(11):26087-26124. DOI: 10.3390/ijms161125942
  126. 126. Sanchez-Valle V, Chavez-Tapia NC, Uribe M, Mendez-Sanchez N. Role of oxidative stress and molecular changes in liver fibrosis: A review. Current Medicinal Chemistry. 2012;19(28):4850-4860. DOI: 10.2174/092986712803341520
  127. 127. Heeba GH, Mahmoud ME. Therapeutic potential of morin against liver fibrosis in rats: Modulation of oxidative stress, cytokine production and nuclear factor kappa B. Environmental Toxicology and Pharmacology. 2014;37(2):662-671. DOI: 10.1016/j.etap.2014.01.026
  128. 128. Li S, Hong M, Tan HY, Wang N, Feng Y. Insights into the role and interdependence of oxidative stress and inflammation in liver diseases. Oxidative Medicine and Cellular Longevity. 2016;2016:1-21. DOI: 10.1155/2016/4234061
  129. 129. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350-355 [PMID: 15372042 DOI: 10.1038/nature02871]
  130. 130. He Y, Huang C, Zhang SP, Sun X, Long XR, Li J. The potential of microRNAs in liver fibrosis. Cellular Signalling. 2012;24(12):2268-2272. DOI: 10.1016/j.cellsig.2012.07.023
  131. 131. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. Journal of Hepatology. 2013;58(2):234-239. DOI: 10.1016/j.jhep.2012.10.015
  132. 132. Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatology Research.2017;47(1):60-69. DOI: 10.1111/hepr.12730
  133. 133. Zhang Z, Gao Z, Hu W, Yin S, Wang C, Zang Y, et al. 3,3′-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. British Journal of Pharmacology. 2013;170(3):649-660. DOI: 10.1111/bph.12323
  134. 134. Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. Cancer Research. 2015;75(9):1859-1867. DOI: 10.1158/0008-5472.CAN-14-1254
  135. 135. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, et al. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE. 2011;6(1):e16081. DOI: 10.1371/journal.pone.0016081
  136. 136. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012;61(11):1600-1609. DOI: 10.1136/gutjnl-2011-300717
  137. 137. Roderburg C, Mollnow T, Bongaerts B, Elfimova N, Vargas Cardenas D, Berger K, et al. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS ONE. 2012;7(3):e32999. DOI: 10.1371/journal.pone.0032999
  138. 138. Okada H, Honda M, Campbell JS, Takegoshi K, Sakai Y, Yamashita T, et al. Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice. Cancer Science. 2015;106(9):1143-1152. DOI: 10.1111/cas.12730
  139. 139. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, et al. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair. 2012;5(1):12. DOI: 10.1186/1755-1536-5-12
  140. 140. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. AJP: Gastrointestinal and Liver Physiology. 2010;298(1):G101-G106. DOI: 10.1152/ajpgi.00220.2009
  141. 141. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53(1):209-218. DOI: 10.1002/hep.23922
  142. 142. Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Mollnow T, Zimmermann HW, et al. miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. Journal of Hepatology. 2013;58(4):736-742. DOI: 10.1016/j.jhep.2012.11.022
  143. 143. Tu T, Calabro SR, Lee A, Maczurek AE, Budzinska MA, Warner FJ, et al. Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis? Journal of Gastroenterology and Hepatology. 2015;30(12):1696-1704. DOI:10.1111/jgh.13065
  144. 144. Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz AJ, García-Peñarrubia P. Inflammatory status in human hepatic cirrhosis. World Journal of Gastroenterology. 2015;21(41):11522-15411. DOI: 10.3748/wjg.v21.i41.11522
  145. 145. Schuppan D, Cramer T, Bauer M, Strefeld T, Hahn EG, Herbst H. Hepatocytes as a source of collagen type XVIII endostatin. Lancet. 1998;352(9131):879-880. DOI: 10.1016/S0140-6736(05)60006-2
  146. 146. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Seminars in Liver Disease. 2001;21(3): 351-372. DOI: 10.1055/s2001-17556
  147. 147. Myers JC, Li D, Bageris A, Abraham V, Dion AS, Amenta PS. Biochemical and immunohistochemical characterization of human type XIX defines a novel class of basement membrane zone collagens. American Journal of Pathology. 1997;151(6):1729-1740 PMID: 9403723
  148. 148. Schuppan D. Structure of the extracellular matrix in normal and fibrotic liver: Collagens and glycoproteins. Seminars in Liver Disease. 1990;10(1):1-10. DOI: 10.1055/s-2008-1040452
  149. 149. Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Seminars in Liver Disease. 2001;21(3):373-384. DOI: 10.1055/s-2001-17552
  150. 150. Baiocchini A, Montaldo C, Conigliaro A, Grimaldi A, Correani V, Mura F, et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution. PLoS ONE. 2016;11(3):e0151736. DOI: 10.1371/journal.pone.0151736
  151. 151. van Dijk F, Olinga P, Poelstra K, Beljaars L. Targeted therapies in liver fibrosis: Combining the best parts of platelet-derived growth factor BB and interferon gamma. Frontiers in Medicine (Lausanne). 2015;2:72. DOI: 10.3389/fmed.2015.00072
  152. 152. Toosi AE. Liver fibrosis: Causes and methods of assessment, a review. Romanian Journal of Internal Medicine. 2015;53(4):304-314. 10.1515/rjim-2015-0039
  153. 153. Sun M, Kisseleva T. Reversibility of liver fibrosis. Clinics and Research in Hepatology and Gastroenterology. 2015;39(Suppl 1):S60–S63. DOI: 10.1016/j.clinre.2015.06.015
  154. 154. Friedman SL. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiological Reviews. 2008;88(1):125-172. DOI: 10.1152/physrev.00013.2007
  155. 155. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therapeutic Advances in Gastroenterology. 2011;4(6):391-417. DOI: 10.1177/1756283X11413002
  156. 156. Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. Journal of Clinical Investigation. 2013;123(5):1902-1910. DOI: 10.1172/jci66369
  157. 157. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655-1669. DOI:10.1053/j.gastro.2008.03.003
  158. 158. Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: Concept to treatment. Journal of Hepatology. 2015;62(1):S15–S24. DOI: 10.1016/j.jhep.2015.02.039
  159. 159. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis. Gastroenterology. 2002;123(4):1323-1330. DOI: 10.1053/gast.2002.35953
  160. 160. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. Journal of Hepatology. 2002;36(2):200-209. DOI: 10.1016/s0168-8278(01)00260-4
  161. 161. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Seminars in Liver Disease. 2001;21(3):397-416. DOI: 10.1055/s-2001-17554
  162. 162. Maher JJ, Lozier JS, Scott MK. Rat hepatic stellate cells produce cytokine-induced neutrophil chemoattractant in culture and in vivo. American Journal of Physiology. 1998;275(4pt1):G847–G853. PMID: 9756517
  163. 163. Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World Journal of Gastroenterology. 2016;22(48):10512-10522. DOI: 10.3748/wjg.v22.i48.10512
  164. 164. Pradere JP, Kluwe J, De Minicis S, Jiao JJ, Gwak GY, Dapito DH, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology. 2013;58(4):1461-1473. DOI: 10.1002/hep.26429
  165. 165. Barnes MA, McMullen MR, Roychowdhury S, Madhun NZ, Niese K, Olman MA, et al. Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis. Journal of Leukocyte Biology. 2015;97(1):161-169. DOI: 10.1189/jlb.3A0614-280R
  166. 166. Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, et al. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut. 2014;63(12):1960-1971. DOI: 10.1136/gutjnl-2013-306294
  167. 167. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 2006;130(2):435-452. DOI: 10.1053/j.gastro.2005.10.055
  168. 168. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology. 2001;34(1):3-6. DOI: 10.1053/jhep.2001.25173
  169. 169. Ebrahimi H, Naderian M, Sohrabpour AA. New concepts on pathogenesis and diagnosis of liver fibrosis; a review article. Middle East Journal of Digestive Diseases. 2016;8(3):166-178. DOI: 10.15171/mejdd.2016.29
  170. 170. Choi ET, Callow AD, Sehgal NL, Brown DM, Ryan US. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intima hyperplasia. Archives of Surgery. 1995;130(3):257-261. DOI: 10.1001/archsurg.1995.01430030027004
  171. 171. Pines M, Spector I. Halofuginone—The multifaceted molecule. Molecules. 2015;20(1):573-594. DOI: 10.3390/molecules20010573
  172. 172. Giannelli G, Mikulits W, Dooley S, Fabregat I, Moustakas A, ten Dijke P, et al. The rationale for targeting TGF-β in chronic liver diseases. European Journal of Clinical Investigation. 2016;46(4):349-361. DOI: 10.1111/eci.12596
  173. 173. Roberts AB, Russo A, Felici A, Flanders KC. Smad3: A key player in pathogenetic mechanisms dependent on TGF-β. Annals of the New York Academy of Sciences. 2003;995(1):1-10. DOI: 10.1111/j.1749-6632.2003.tb03205.x
  174. 174. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and {alpha}-smooth muscle actin organization. Molecular Biology of the Cell. 2005;16(9):4214-4224. DOI: 10.1091/mbc.e05-02-0149
  175. 175. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: Implication in fibrosis. Experimental Biology and Medicine (Maywood). 2002;227(5):301-314. PMID: 11976400
  176. 176. Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, et al. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscular Disorders. 2008;18(11):857-868. DOI: 10.1016/j.nmd.2008.06.386
  177. 177. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. Journal of Investigative Dermatology. 2002;118(3):461-470. DOI: 10.1046/j.0022-202x.2001.01690
  178. 178. Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, et al. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas. 2009;38(4):427-435. DOI: 10.1097/MPA.0b013e3181967670
  179. 179. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, et al. Amelioration of radiation induced fibrosis: Inhibition of transforming growth factor-beta signaling by halofuginone. Journal of Biological Chemistry. 2004;279(15):15167-15176. DOI: 10.1074/jbc.M309798200
  180. 180. Yee KO, Connolly CM, Pines M, Lawler J. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biology & Therapy. 2006;5(2):218-224. DOI: 10.4161/cbt.5.2.2419
  181. 181. Gnainsky Y, Kushnirsky Z, Bilu G, Hagai Y, Genina O, Volpin H, et al. Gene expression during chemically induced liver fibrosis: Effect of halofuginone on TGF-beta signaling. Cell and Tissue Research. 2007;328(1):153-166. DOI: 10.1007/s00441-006-0330-1
  182. 182. Roffe S, Hagai Y, Pines M, Halevy O. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: Effect on myotube fusion. Experimental Cell Research. 2010;316(6):1061-1069. DOI: 10.1016/j.yexcr.2010.01.003
  183. 183. Zeplin PH. Halofuginone down-regulates Smad3 expression and inhibits the TGFbeta-induced expression of fibrotic markers in human corneal fibroblasts. Annals of Plastic Surgery. 2014;72(4):489. DOI: 10.1097/SAP.0b013e31828a49e3
  184. 184. Nagler A, Genina O, Lavelin I, Ohana M, Pines M. Halofuginone: An inhibitor of collagen type I synthesis: Prevents formation of post-operative adhesions formation in the rat uterine horn model. American Journal of Obstetrics and Gynecology. 1999;180(3):558-563. DOI: 10.1016/s0002-9378(99)70254-1
  185. 185. Nagler A, Katz A, Aingorn H, Miao HQ, Condiotti R, Genina O, Pines M, et al. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney International. 1997;52(6):1561-1569. DOI: 10.1038/ki.1997.486
  186. 186. Pines M. Targeting TGFβ signaling to inhibit fibroblasts activation as a therapy forfibrosis and cancer. Expert Opinion on Drug Discovery. 2008;3(1):11-20. DOI: 10.1517/17460441.3.1.11
  187. 187. Pines M. Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World Journal of Gastroenterology. 2014;20(40):14778-14786. DOI: 10.3748/wjg.v20.i40.14778
  188. 188. Sundrud MS, Koralov SB, Feuerer M, Calado DP, Kozhaya AE, Rhule-Smith A, et al. Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science. 2009;324(5932):1334-1338. DOI: 10.1126/science.1172638
  189. 189. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F, et al. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS ONE. 2011;6(7):e22770. DOI: 10.1371/journal.pone.0022770
  190. 190. Keller TL, Zocco D, Sundrud MS, Hendrick M, Edenius M, Yum J, et al. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nature Chemical Biology. 2012;8(3):311-317. DOI: 10.1038/nchembio.790
  191. 191. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006;441(7090):231-234. DOI: 10.1038/nature04754
  192. 192. Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Abu-Amara SN, et al. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. Journal of Hepatology. 2004;40(2):269-277. PMID: 14739098
  193. 193. Gnainsky Y, Spira G, Paizi M, Bruck R, Nagler A, Genina O, et al. The involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis–effect of halofuginone. Cell and Tissue Research. 2006;324(3):385-394. DOI: 10.1007/s00441-005-0092-1
  194. 194. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3):512-527. DOI: 10.1053/j.gastro.2013.01.002
  195. 195. Nissen NN, Martin P. Hepatocellular carcinoma: The high-risk patient. Journal of Clinical Gastroenterology. 2002;35(5 Suppl 2):S79–S85. DOI: 10.1097/00004836-200211002-00003
  196. 196. Nagler A, Ohana M, Shibolet O, Shapira MY, Alper R, Vlodavsky I, et al. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. European Journal of Cancer. 2004;40(9):1397-1403. DOI: 10.1016/j.ejca.2003.11.036
  197. 197. Taras D, Blanc JF, Rullier A, Dugot-Senant N, Laurendeau I, Bièche I, et al. Halofuginone suppresses the lung metastasis of chemically induced hepatocellular carcinoma in rats through MMP inhibition. Neoplasia. 2006;8(4):312-318. DOI: 10.1593/neo.05796


  • The author reports no conflicts of interest.

Written By

Berna Karakoyun

Submitted: November 30th, 2016 Reviewed: March 20th, 2017 Published: July 5th, 2017